Kockx M, Gervois P P, Poulain P, Derudas B, Peters J M, Gonzalez F J, Princen H M, Kooistra T, Staels B
Gaubius Laboratory, TNO-Prevention and Health, Leiden, The Netherlands; U.325 INSERM, Département d'Athérosclerose, Institut Pasteur, Lille, France.
Blood. 1999 May 1;93(9):2991-8.
Plasma fibrinogen levels have been identified as an important risk factor for cardiovascular diseases. Among the few compounds known to lower circulating fibrinogen levels in humans are certain fibrates. We have studied the regulation of fibrinogen gene expression by fibrates in rodents. Treatment of adult male rats with fenofibrate (0.5% [wt/wt] in the diet) for 7 days decreased hepatic Aalpha-, Bbeta-, and gamma-chain mRNA levels to 52% +/- 7%, 46% +/- 8%, and 81% +/- 19% of control values, respectively. In parallel, plasma fibrinogen concentrations were decreased to 63% +/- 7% of controls. The suppression of fibrinogen expression was dose-dependent and was already evident after 1 day at the highest dose of fenofibrate tested (0.5% [wt/wt]). Nuclear run-on experiments showed that the decrease in fibrinogen expression after fenofibrate occurred at the transcriptional level, as exemplified for the gene for the Aalpha-chain. Other fibrates tested showed similar effects on fibrinogen expression and transcription. The effect of fibrates is specific for peroxisome proliferator-activated receptor-alpha (PPARalpha) because a high-affinity ligand for PPARgamma, the thiazolidinedione BRL 49653, lowered triglyceride levels, but was unable to suppress fibrinogen expression. Direct evidence for the involvement of PPARalpha in the suppression of fibrinogen by fibrates was obtained using PPARalpha-null (-/-) mice. Compared with (+/+) mice, plasma fibrinogen levels in (-/-) mice were significantly higher (3.20 +/- 0.48 v 2.67 +/- 0.42 g/L). Also, hepatic fibrinogen Aalpha-chain mRNA levels were 25% +/- 11% higher in the (-/-) mice. On treatment with 0.2% (wt/wt) fenofibrate, a significant decrease in plasma fibrinogen to 77% +/- 10% of control levels and in hepatic fibrinogen Aalpha-chain mRNA levels to 65% +/- 12% of control levels was seen in (+/+) mice, but not in (-/-) mice. These studies show that PPARalpha regulates basal levels of plasma fibrinogen and establish that fibrate-suppressed expression of fibrinogen in rodents is mediated through PPARalpha.
血浆纤维蛋白原水平已被确认为心血管疾病的一个重要危险因素。在已知能降低人体循环纤维蛋白原水平的少数化合物中,某些贝特类药物是其中之一。我们研究了贝特类药物对啮齿动物纤维蛋白原基因表达的调控作用。用非诺贝特(饮食中0.5%[重量/重量])处理成年雄性大鼠7天,肝α-A、β-B和γ链mRNA水平分别降至对照值的52%±7%、46%±8%和81%±19%。同时,血浆纤维蛋白原浓度降至对照值的63%±7%。纤维蛋白原表达的抑制呈剂量依赖性,在测试的最高剂量非诺贝特(0.5%[重量/重量])处理1天后就已明显。核转录实验表明,非诺贝特处理后纤维蛋白原表达的降低发生在转录水平,以α-A链基因为例。测试的其他贝特类药物对纤维蛋白原表达和转录也有类似作用。贝特类药物的作用对过氧化物酶体增殖物激活受体-α(PPARα)具有特异性,因为PPARγ的高亲和力配体噻唑烷二酮BRL 49653可降低甘油三酯水平,但无法抑制纤维蛋白原表达。使用PPARα基因敲除(-/-)小鼠获得了PPARα参与贝特类药物抑制纤维蛋白原的直接证据。与(+/+)小鼠相比,(-/-)小鼠的血浆纤维蛋白原水平显著更高(3.20±0.48对2.67±0.42 g/L)。此外,(-/-)小鼠肝纤维蛋白原α-A链mRNA水平高25%±11%。用0.2%(重量/重量)非诺贝特处理后,(+/+)小鼠的血浆纤维蛋白原显著降至对照水平的77%±10%,肝纤维蛋白原α-A链mRNA水平降至对照水平的65%±12%,而(-/-)小鼠则未出现这种情况。这些研究表明PPARα调节血浆纤维蛋白原的基础水平,并证实贝特类药物在啮齿动物中抑制纤维蛋白原表达是通过PPARα介导的。